H1N1 COUNTERMEASURES STRATEGY AND ... - PHE Home
H1N1 COUNTERMEASURES STRATEGY AND ... - PHE Home
H1N1 COUNTERMEASURES STRATEGY AND ... - PHE Home
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
NBSB Pandemic Influenza Working Group<br />
Detailed Report<br />
michael.mcguire@roche.com<br />
Vas Narasimhan, M.D., MPP<br />
CEO Vaccines North America<br />
President, Vaccines USA<br />
Novartis Vaccines & Diagnostics Inc.<br />
350 Massachusetts Avenue<br />
Cambridge, MA 02139 USA<br />
617-871-3350 (Office)<br />
vas.narasimhan@novartis.com<br />
Judith Ng-Cashin, M.D.<br />
Vice President<br />
Global Clinical Development<br />
Infectious Diseases<br />
GlaxoSmithKline<br />
919-483-1514 (Office)<br />
judith.x.ng-cashin@gsk.com<br />
Rino Rappuoli, Ph.D.<br />
Global Head Vaccines Research<br />
Novartis Vaccines and Diagnostics<br />
Via Fiorentina 1<br />
53100 Siena, Italy<br />
+39-0577-243414 (Office)<br />
Rino.rappuoli@novartis.com<br />
Miklos Salgo, M.D., Ph.D., FACP<br />
Cluster Head, Virology<br />
Drug Safety Risk Management<br />
Hoffmann La Roche, Inc.<br />
340 Kingsland St.<br />
Nutley, NJ 07110<br />
973-652-3587<br />
miklos.salgo@roche.com<br />
William Sheridan, M.B., B.S.<br />
Senior Vice President<br />
Chief Medical Officer<br />
BioCryst Pharmaceuticals<br />
2425 Kildaire Farm Road, Suite 106<br />
Cary, NC 27518<br />
919-859-1302 (Office)<br />
bsheridan@biocryst.com<br />
Gale Smith, Ph.D.<br />
Vice President, Vaccine Development<br />
Novavax, Inc.<br />
9920 Belward Campus Drive<br />
Rockville, MD 20850<br />
240-268-2000, ext 2027 (Office)<br />
gsmith@novavax.com<br />
Raymond Taylor<br />
VP Program Management<br />
Peramivir Program Leader<br />
BioCryst Pharmaceuticals<br />
2425 Kildaire Farm Road, Suite 106<br />
Cary, NC 27518<br />
919-859-7915 (Office)<br />
rtaylor@biocryst.com<br />
Participant List<br />
Russell Thirsk<br />
Global Head, Influenza Franchise<br />
Novartis Vaccines and Diagnostics<br />
350 Massachusetts Ave<br />
Cambridge, MA 02139<br />
617-871-7998 (Office)<br />
Russell.thirsk@novartis.com<br />
Seth Toback, M.D., MMM, FAAP<br />
Associate Director, Medical Affairs<br />
MedImmune, LLC<br />
One MedImmune Way<br />
Gaithersburg, MD 20878<br />
301-398-4734 (Office)<br />
tobacks@medimmune.com<br />
Theodore F. Tsai, M.D., M.P.H., FIDSA<br />
Sr. VP, Scientific Affairs<br />
Novartis Vaccines and Diagnostics<br />
350 Massachusetts Ave<br />
Cambridge, MA 02139<br />
617-871-8052 (Office)<br />
theodore.tsai@novartis.com<br />
Angela Windt, PharmD<br />
U.S. Regulatory Partner, Tamiflu<br />
Hoffmann La Roche, Inc.<br />
340 Kingsland St.<br />
Nutley, NJ 07110<br />
973-235-5268 (Office)<br />
angela.windt@roche.com<br />
U.S. Government Invitees<br />
Charla Andrews, Sc.M., RAC (US)<br />
Staff Scientist<br />
Vaccine Production Program, Regulatory Affairs<br />
Vaccine Research Center<br />
National Institute of Allergy and Infectious Diseases<br />
National Institutes of Health<br />
Building 40, Room 5508, MSC 3011<br />
40 Convent Drive<br />
Bethesda, MD 20892-3011<br />
301-594-8488 (Office)<br />
candrews@nih.gov<br />
Luciana Borio, M.D.<br />
Senior Science Advisor<br />
Office of the Chief Scientist<br />
Office of the Commissioner<br />
U.S. Food and Drug Administration<br />
U.S. Department of Health and Human Services<br />
White Oak, Building 1, #2318<br />
10903 New Hampshire Ave.<br />
Silver Spring, MD 20993<br />
301-796-4637 (Office)<br />
Luciana.borio@fda.hhs.gov<br />
Debra Birnkrant<br />
Director, Division of Antiviral Products<br />
Office of Antimicrobial Products<br />
Office of New Drugs<br />
4
Change language